Tyrosine kinase inhibitors (TKIs), mTOR inhibitors, and VEGF inhibitors are molecularly targeted drugs frequently used to treat RCC and have been demonstrated to improve the overall prognosis of patients with unresectable or metastatic RCC. The gene discussed is MTOR; the disease is renal cell carcinoma.